Copyright investors
On Friday, AstraZeneca ADR (AZN) reached a noteworthy performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 78 the day before. IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database. Decades of market research reveals that the stocks that go on to make the biggest gains often have an 80 or better RS Rating in the early stages of their moves. While the stock is not near an ideal buy point right now, see if it goes on to form and break out of a proper consolidation. The company reported 14% EPS growth in the latest quarterly report, while sales growth came in at 12%. AstraZeneca ADR earns the No. 3 rank among its peers in the Medical-Diversified industry group. Eli Lilly (LLY) is the top-ranked stock within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
